Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Glycanostics logo — Our patented technology for screening cancers detects change...

Glycanostics

Our patented technology for screening cancers detects changes in a glycan attached to proteins in the blood

Founded 2017 Slovakia Slovakia 20 employees

General Information

Company Name Glycanostics
Founded Year 2017
Location Slovakia Slovakia +1
Employees 20
Social

Get notified when Glycanostics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Glycanostics

Glycanostics is an innovative start-up company established in 2017 to bring its revolutionary cancer diagnostics products to the US and EU markets. The company was founded by two remarkable scientists PhD Jan Tkac and PhD Tomas Bertok who got international recognition for their scientific works, prestigious grants and awards winners such as Scientists of the year (Slovakia), European Research Council (ERC) Consolidator grant, Marie Skłodowska-Curie actions ITN, Qatar National Research Fund. The mission of Glycanostics is to establish glycan-based, accurate, affordable and non-invasive tests for cancer diagnostics in early stages which could save thousands of people’s lives and prevent unnecessary treatment. Diagnostics is done by the analysis of glycan changes on specific proteins like a prostate-specific antigen (PSA) in a non-invasive way i.e. directly in human serum. Thus, molecular changes of the proteins like PSA are applied for cancer diagnostics. The tests are designed to help doctors to make a proper decision about a need to perform a biopsy or to check the patient after the biopsy which misses 30% of prostate cancer patients. Prostate cancer disease can be treatable and early diagnostics is the key!

No funding data available for Glycanostics yet.

Get notified when Glycanostics raises funding

Latest News

View All
EIC Scaling Club'a katılan 72 teknoloji şirketi — Webrazzi
EIC Scaling Club'a katılan 72 teknoloji şirketi
Webrazzi Oct 21, 2024

Glycanostics Alternatives & Competitors

Glycanostics vs
Wren Laboratories
Wren Laboratories United States

Unleashing the Power of mRNA and AI for Cancer Diagnostics

25 employees
Biotechnology, Health Care
Glycanostics vs
Signature Diagnostics GmbH
Signature Diagnostics GmbH

Signature Diagnostics AG, established in 2004 and located in Potsdam, Germany, specializes in transl...

Series C
Biotechnology, Health Care
Glycanostics vs
Universal Diagnostics S.A.
Universal Diagnostics S.A. Spain

We will WIN the FIGHT against CANCER

Series B
123 employees
Biopharma, Biotechnology

FAQ About Glycanostics

Our patented technology for screening cancers detects changes in a glycan attached to proteins in the blood
Glycanostics was founded in 2017.
Glycanostics is headquartered in Slovakia.
Glycanostics has approximately 20 employees.
Top alternatives and competitors to Glycanostics include Wren Laboratories, Signature Diagnostics GmbH, Universal Diagnostics S.A., Oasis Diagnostics® Corporation, Savicell. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Glycanostics and Wren Laboratories are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Glycanostics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy